Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

The immunogenicity of protein therapeutics has so far proven to be difficult to predict in patients, with many biologics inducing undesirable immune responses directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and occasionally life threatening autoimmunity. The most common effect of administrating an immunogenic protein therapeutic is the development of a high affinity anti-therapeutic antibody response. Furthermore, it is clear from clinical studies that protein therapeutics derived from endogenous human proteins are capable of stimulating undesirable immune responses in patients, and as a consequence, the prediction and reduction of immunogenicity has been the focus of intense research. This review will outline the principle causes of the immunogenicity in protein therapeutics, and describe the development of pre-clinical models that can be used to aid in the prediction of the immunogenic potential of novel protein therapeutics prior to administration in man.

[1]  C. Janeway.  Approaching the asymptote? Evolution and revolution in immunology. , 1989, Cold Spring Harbor symposia on quantitative biology.

[2]  R. Zinkernagel,et al.  Neutralizing antiviral B cell responses. , 1997, Annual review of immunology.

[3]  T. Jones,et al.  New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development , 2008, Drugs in R&D.

[4]  B. Heyman,et al.  Antibody Production in Mice Deficient for Complement Receptors 1 and 2 Can Be Induced by IgG/Ag and IgE/Ag, But Not IgM/Ag Complexes1 , 2000, The Journal of Immunology.

[5]  J. Murray,et al.  HLA-DQ Determines the Response to Exogenous Wheat Proteins: A Model of Gluten Sensitivity in Transgenic Knockout Mice1 , 2002, The Journal of Immunology.

[6]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[7]  M. Reding,et al.  Distribution of Th1- and Th2-induced Anti-factor VIII IgG Subclasses in Congenital and Acquired Hemophilia Patients , 2002, Thrombosis and Haemostasis.

[8]  G. Alexander,et al.  The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[9]  J C Ryff,et al.  Clinical investigation of the immunogenicity of interferon-alpha 2a. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  N. Key,et al.  CD4+ T Cell Response to Factor VIII in Hemophilia A, Acquired Hemophilia, and Healthy Subjects , 1999, Thrombosis and Haemostasis.

[11]  A. Woods,et al.  An HLA-DR 1 Transgene Confers Susceptibility to Collagen-induced Arthritis Elicited with Human Type II Collagen , 1997 .

[12]  P. Coulie,et al.  Enhancement of IgG anti‐carrier responses by IgG2 anti‐hapten antibodies in mice , 1985, European journal of immunology.

[13]  T. de Ståhl,et al.  A Role for Complement in Feedback Enhancement of Antibody Responses by IgG3 , 2003, The Journal of experimental medicine.

[14]  R. Steinman,et al.  Differential Antigen Processing by Dendritic Cell Subsets in Vivo , 2007, Science.

[15]  Marcia Stickler,et al.  Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope , 2004, The Journal of Immunology.

[16]  M. Nussenzweig,et al.  A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling , 1994, Nature.

[17]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[18]  B. Heyman,et al.  IgG2a-Mediated Enhancement of Antibody and T Cell Responses and Its Relation to Inhibitory and Activating Fcγ Receptors1 , 2004, The Journal of Immunology.

[19]  M. Reding.  Immunological aspects of inhibitor development , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  A. Valdés,et al.  The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4+ T-cell epitope in human interferon-β , 2004, Genes and Immunity.

[21]  A. DeFranco,et al.  Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. , 2008, Immunity.

[22]  Christopher C. Goodnow,et al.  C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.

[23]  G. Giovannoni,et al.  The Rebif® New Formulation Story , 2007, Drugs in R&D.

[24]  A. Erdei,et al.  Expression and role of Fc- and complement-receptors on human dendritic cells. , 2006, Immunology letters.

[25]  B. Heyman,et al.  Studies on the Mechanism by Which Antigen‐Specific IgG Suppresses Primary Antibody Responses: Evidence for Epitope Masking and Decreased Localization of Antigen in the Spleen , 2009, Scandinavian journal of immunology.

[26]  P. Carrieri,et al.  Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory , 2002, Journal of neurology, neurosurgery, and psychiatry.

[27]  S. Madoiwa,et al.  Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A , 2004, Journal of thrombosis and haemostasis : JTH.

[28]  B. Dijkmans,et al.  Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study , 2009, Annals of the rheumatic diseases.

[29]  T. Ohmori,et al.  Induction of factor VIII‐specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[30]  R. G. Das,et al.  Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. , 2000, Immunology.

[31]  R. Zinkernagel,et al.  Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies , 1997, The Journal of experimental medicine.

[32]  T. Baglin,et al.  Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII , 2005, Journal of thrombosis and haemostasis : JTH.

[33]  R M Zinkernagel,et al.  How many specific B cells are needed to protect against a virus? , 1994, Journal of immunology.

[34]  Huub Schellekens,et al.  Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. , 2006, Journal of Pharmacy and Science.

[35]  E. Santagostino,et al.  International workshop on immune tolerance induction: consensus recommendations 1 , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[36]  M. Billeter,et al.  T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses , 1998, Nature Medicine.

[37]  W. Fridman,et al.  Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. , 1992, Science.

[38]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[39]  B. Heyman,et al.  Complement activation is required for IgM-mediated enhancement of the antibody response , 1988, The Journal of experimental medicine.

[40]  C. Figdor,et al.  Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. , 2005, Blood.

[41]  J. Kearney,et al.  Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. , 2001, Immunity.

[42]  P. V. van Riel,et al.  Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[43]  S. A. Marshall,et al.  Rational design and engineering of therapeutic proteins. , 2003, Drug discovery today.

[44]  T. Jones,et al.  Identification and removal of immunogenicity in therapeutic proteins. , 2007, Current opinion in drug discovery & development.

[45]  F. Carr,et al.  Deimmunization of monoclonal antibodies. , 2009, Methods in molecular biology.

[46]  Patrick Mayeux,et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.

[47]  N. Hacohen,et al.  Carbohydrate‐Mediated Targeting of Antigen to Dendritic Cells Leads to Enhanced Presentation of Antigen to T Cells , 2008, Chembiochem : a European journal of chemical biology.

[48]  John Sidney,et al.  Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity , 2005, The Journal of Immunology.

[49]  Ryff Jc,et al.  Clinical investigation of the immunogenicity of interferon-alpha 2a. , 1997 .

[50]  N. G. Groot,et al.  Major histocompatibility complex class II polymorphisms in primates , 1999, Immunological reviews.

[51]  J. Tcheng,et al.  Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. , 2003, Developments in biologicals.

[52]  R. Dubridge,et al.  The immunogenicity of humanized and fully human antibodies , 2010, mAbs.

[53]  F. Gage,et al.  Development of functional human embryonic stem cell-derived neurons in mouse brain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[55]  J. Vielmetter,et al.  Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. , 2006, Clinical immunology.

[56]  L. Old,et al.  Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. , 2001, Cancer research.

[57]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[58]  Christoph Schaniel,et al.  Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation , 1998, European journal of immunology.

[59]  H. Scher,et al.  Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. , 2008, Journal of Clinical Oncology.

[60]  S. Holmes,et al.  Human population-based identification of CD4(+) T-cell peptide epitope determinants. , 2003, Journal of immunological methods.

[61]  J. Cerottini,et al.  The immunosuppressive effect of passively administered antibody IgG fragments. , 1969, Journal of immunology.

[62]  S. Cook,et al.  Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients , 2001, Neurology.

[63]  D. Podolsky,et al.  Mucosal antigen presentation and the control of tolerance and immunity. , 2001, Trends in immunology.

[64]  C. Maury,et al.  Induction of tolerance to recombinant therapeutic proteins. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[65]  L. Aarden,et al.  Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[66]  Jochem Alsenz,et al.  Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.

[67]  D. Okita,et al.  Human CD4+ T‐cell epitope repertoire on the C2 domain of coagulation factor VIII , 2003, Journal of thrombosis and haemostasis : JTH.

[68]  S. Vallabhajosula,et al.  Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity , 2005, Clinical Cancer Research.

[69]  G. Klaus.  Generation of memory cells. III. Antibody class requirements for the generation of B-memory cells by antigen--antibody complexes. , 1979, Immunology.

[70]  S. Diebold.  Activation of dendritic cells by toll-like receptors and C-type lectins. , 2009, Handbook of experimental pharmacology.

[71]  P. De Baetselier,et al.  Regulation of Dendritic Cell Numbers and Maturation by Lipopolysaccharide in Vivo , 1996 .

[72]  D. Okita,et al.  Epitope repertoire of human CD4+ T cells on the A3 domain of coagulation factor VIII , 2004, Journal of thrombosis and haemostasis : JTH.

[73]  N. Key,et al.  Sensitization of CD4+ T Cells to Coagulation Factor VIII: Response in Congenital and Acquired Hemophilia Patients and in Healthy Subjects , 2000, Thrombosis and Haemostasis.

[74]  A. Jaber,et al.  Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. , 2007, Journal of pharmaceutical and biomedical analysis.

[75]  Markus G. Manz,et al.  Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.

[76]  Mamoru Ito,et al.  The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice). , 2009, International immunology.

[77]  Mikael Karlsson,et al.  FcγRIIB in IgG-Mediated Suppression of Antibody Responses: Different Impact In Vivo and In Vitro1 , 2001, The Journal of Immunology.

[78]  B. Heyman,et al.  Complement activation is not required for IgG‐mediated suppression of the antibody response , 1988, European journal of immunology.

[79]  G. Porro,et al.  Adalimumab for the treatment of Crohn’s disease , 2008, Biologics : targets & therapy.

[80]  H. Heimpel,et al.  Roferon (rIFN-α2a) Is More Immunogenic Than Intron A (rIFN-α2b) in Patients with Chronic Myelogenous Leukemia , 1994 .

[81]  T. Geijtenbeek,et al.  Self- and nonself-recognition by C-type lectins on dendritic cells. , 2004, Annual review of immunology.

[82]  B Stubinski,et al.  Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results , 2009, Multiple sclerosis.

[83]  S. Ménard,et al.  Cross‐talk between Toll‐like receptors 5 and 9 on activation of human immune responses , 2007, Journal of leukocyte biology.

[84]  N. Greenspan,et al.  Intermolecular cooperativity: a clue to why mice have IgG3? , 1992, Immunology today.

[85]  A. Bertolotto,et al.  Cotugno and cerebrospinal fluid , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[86]  R. Vabulas,et al.  Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells , 1998, European journal of immunology.

[87]  K. Honda,et al.  Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon induction , 2005, Nature.

[88]  C. Snapper,et al.  B‐cell activation by T‐cell‐independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms , 2000, Immunological reviews.

[89]  S. Holmes,et al.  An in vitro human cell-based assay to rank the relative immunogenicity of proteins. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[90]  S. Larson,et al.  Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer , 2005, Clinical Cancer Research.

[91]  S. Larson,et al.  Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy , 2008, Journal of Nuclear Medicine.